

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

Marijo Bilusic ¹, Sheri McMahon,¹ Ravi A Madan ¹, Fatima Karzai ¹, Yo-Ting Tsai,² Renee N Donahue,² Claudia Palena,² Caroline Jochems ², Jennifer L Marté,¹ Charalampos Floudas ¹, Julius Strauss,² Jason Redman,¹ Houssein Abdul Sater ¹, Shahrooz Rabizadeh,³ Patrick Soon-Shiong,³ Jeffrey Schlom ², James L Gulley ¹

To cite: Bilusic M, McMahon S, Madan RA, *et al.* Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). *Journal for ImmunoTherapy of Cancer* 2021;9:e002374. doi:10.1136/jitc-2021-002374

Accepted 21 February 2021



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

¹Genitourinary Malignancy Branch, National Cancer Institute, Bethesda, Maryland, USA

²Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland, USA

³ImmunityBio, Culver City, California, USA

Correspondence to

Dr Marijo Bilusic;
marijo.bilusic@nih.gov

ABSTRACT

Background Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1–, E2b–] targeting three TAAs—prostate-specific antigen (PSA), brachyury, and MUC-1—has been developed. Both brachyury and the C-terminus of MUC-1 are overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and have been shown to play an important role in resistance to chemotherapy, epithelial–mesenchymal transition, and metastasis. The transgenes for PSA, brachyury, and MUC-1 all contain epitope modifications for the expression of CD8+ T-cell enhancer agonist epitopes. We report here the first-in-human trial of this vaccine platform.

Methods Patients with mCRPC were given concurrently three vaccines targeting PSA, brachyury, and MUC-1 at 5×10^{11} viral particles (VP) each, subcutaneously every 3 weeks for a maximum of three doses (dose de-escalation cohort), followed by a booster vaccine every 8 weeks for 1 year (dose-expansion cohort only). The primary objective was to determine the safety and the recommended phase II dose. Immune assays and clinical responses were evaluated.

Results Eighteen patients with mCRPC were enrolled between July 2018 and September 2019 and received at least one vaccination. Median PSA was 25.58 ng/mL (range, 0.65–1006 ng/mL). The vaccine was tolerable and safe, and no grade >3 treatment-related adverse events or dose-limiting toxicities (DLTs) were observed. One patient had a partial response, while five patients had confirmed PSA decline and five had stable disease for >6 months. Median progression-free survival was 22 weeks (95% CI: 19.1 to 34). Seventeen (100%) of 17 patients mounted T-cell responses to at least one TAA, whereas 8 (47%) of 17 patients mounted immune responses to all three TAAs. Multifunctional T-cell responses to PSA, MUC-1, and brachyury were also detected after vaccination in the majority of the patients.

Conclusions Ad5 PSA/MUC-1/brachyury vaccine is well tolerated. The primary end points were met and there were no DLTs. The recommended phase II dose is 5×10^{11} VP. The vaccine demonstrated clinical activity, including one partial response and confirmed PSA responses in five patients. Three patients with prolonged PSA responses received palliative radiation therapy. Further research is needed to evaluate the clinical benefit and immunogenicity of this vaccine in combination with other immuno-oncology agents and/or palliative radiation therapy.

Trial registration number NCT03481816.

BACKGROUND

Multiple studies have demonstrated that therapeutic cancer vaccines are safe and can induce specific antitumor immune responses; however, the therapeutic effects observed in clinical trials to date have been modest. Anti-cancer immunization is a complex process and requires an ideal combination of delivery vectors, tumor-associated antigens (TAAs), and routes of administration that can alter the tumor's immunosuppressive mechanisms. The first therapeutic cancer vaccine approved by the US Food and Drug Administration in 2010 was sipuleucel-T (Provenge; Dendreon Corporation, Seattle, Washington, USA) for the treatment of minimally symptomatic or asymptomatic metastatic castration-resistant prostate cancer (mCRPC). This paved the way for the development of other therapeutic cancer vaccines for prostate cancer and other solid tumors. Prostate cancer is an ideal model for cancer vaccine immunotherapy because (a) it is slow-growing, (b)

Table 1 Patient demographics

Baseline characteristics	N=18
Age (years)	
Median (range)	71.6 (54–88)
Race	
White/Caucasian	15
Black	3
ECOG PS (N, %)	
0	7
1	11
Gleason score	
Median (range)	8 (6–9)
Baseline PSA (ng/mL) (range)	25.58 (0.62–1006)
Prior therapies	
Chemotherapy (CSPC)	10
Chemotherapy (CRPC)	6
Therapeutic cancer vaccine	7
Immune checkpoint inhibitor	6
Abiraterone	12
Enzalutamide	12
PARP inhibitors	4
ADT only (mCRPC treatment-naïve)	5
Number of prior mCRPC therapies	
Median (range)	3 (0–7)

ADT, androgen-deprivation therapy; CRPC, castration-resistant prostate cancer; CSPC, castration-sensitive prostate cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Score; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly ADP ribose polymerase; PSA, prostate-specific antigen.

prostate-specific antigen (PSA) is a serum marker that can be easily followed, and (c) the prostate is a non-essential organ with several TAAs that can be easily targeted without off-target toxicity.^{1–3} Another prostate cancer vaccine, PROSTVAC, uses genetically altered poxviruses that deliver the transgenes for PSA to antigen-presenting cells through cellular infection, resulting in the activation of PSA-specific cytolytic T lymphocytes. Despite initial promising results observed in a randomized phase II trial, the placebo-controlled, randomized phase III trial did not show an overall survival (OS) benefit in patients with mCRPC.⁴ Currently, PROSTVAC is being evaluated in combination with other treatment modalities in several ongoing phase II studies.

Adenoviruses (Ads) are a family of DNA viruses with a linear double-stranded genome contained by an icosahedral, non-enveloped capsid.^{5,6} Ads have emerged as leading candidate vectors for cancer vaccines. Adenovirus 5 (Ad5) vectors do not integrate (ie, their genomes remain episomal), and risk for germline transmission and/or insertional mutagenesis is extremely low. A new and advanced generation of Ad5 vectors has been developed that, in addition to deletions in the E1 and E3 gene regions, have deletions in the early 2b (E2b) gene regions

[E1–, E2b–].^{7–9} These non-replicating adenoviral vectors may be able to circumvent or decrease neutralizing antiviral immune responses and enable sustained boosting to maximize immune responses. In preclinical studies, Ad5 [E1–, E2b–] vector-based vaccines were used in multiple homologous immunization regimens where they induced immune responses despite the presence of pre-existing Ad5 immunity.¹⁰ In *in vitro* studies of human dendritic cells and in murine vaccination studies, a multitargeted vaccine based on the Ad5 [E1–, E2b–] platform and containing the TAAs CEA, MUC-1, and brachyury induced immune responses directed against all three target antigens with minimal to no antigenic competition.¹¹

We recently published a phase I study of a TriAdeno vaccine regimen composed of the combination Ad5 vaccines containing the TAAs CEA, MUC-1, and brachyury in patients with advanced cancer. We found that concurrent administration of three Ad5 vaccines is safe and can induce CD4+ and/or CD8+ T-cell responses to at least one TAA encoded by the vaccine with no evidence of antigenic competition.¹²

The phase I study reported here evaluated the safety and tolerability of an admix of three Ad-based vaccines. ETBX-071 is a PSA-targeting vaccine that employs the Ad5 [E1–, E2b–] vector containing a PSA gene insert. ETBX-061 is a MUC-1-targeting vaccine that employs the Ad5 [E1–, E2b–] vector containing a modified MUC-1 (MUC-1C) gene insert. The investigational product ETBX-051 is a brachyury-targeting vaccine that employs the Ad5 [E1–, E2b–] vector containing a modified brachyury gene insert. ETBX-051, ETBX-61, and ETBX-71 were administered to patients at the same time. The overall goal of this study was to expand immunotherapeutic options for the treatment of mCRPC by employing a multitargeted regimen designed to induce broad antitumor immune responses directed against tumors that overexpress PSA, MUC-1, and/or brachyury. This is the first study to evaluate the concurrent use of the Ad5 PSA/MUC-1/brachyury vaccine in patients with mCRPC.

PATIENTS AND METHODS

Eligibility

Eligible patients had to have incurable mCRPC with radiographic disease progression, defined as any new or enlarging bone lesions or growing lymph node disease consistent with prostate cancer or PSA progression. PSA progression was defined as a sequence of rising values separated by >1 week (two separate increasing values over a minimum of 2 ng/mL as per Prostate Cancer Working Group 2 PSA eligibility criteria). Any number of previous treatment options for mCRPC was allowed, with a withdrawal period of 4–6 weeks following discontinuation of bicalutamide, flutamide, or nilutamide. Patients were required to be ≥18 years of age, no other malignancies within 36 months, have an Eastern Cooperative Oncology Group performance status of ≤1, no autoimmune diseases or significant medical illnesses, and acceptable organ function and hematologic parameters. No systemic or local steroids were permitted, except for physiologic replacement doses that were allowed. Patients

Table 2 Adverse events

	Grade 1 N (%)	Grade 2 N (%)	Grade 3 N (%)
Nausea	1 (5.6)	1 (5.6)	0
Headache	1 (5.6)	0	0
Chills	2 (11.1)	0	0
Nasal congestion	1 (5.6)	0	0
Fatigue	4 (22.2)	3 (16.6)	0
Constipation	1 (5.6)	0	0
Hypersomnia	0	2 (11.1)	0
Hypophosphatemia	0	2 (11.1)	0
Anemia	0	1 (5.6)	1 (5.6)
Lung infection	0	0	1 (5.6)
Dehydration	1 (5.6)	0	1 (5.6)
Hypotension	1 (5.6)	0	1 (5.6)
Sinus tachycardia	1 (5.6)	0	0
Atrioventricular block	1 (5.6)	0	0
Ear pain	0	1 (5.6)	0
Abdominal pain	1 (5.6)	1 (5.6)	0
Diarrhea	2 (11.1)	0	0
Gastroesophageal reflux	1 (5.6)	0	0
Hemorrhoidal hemorrhage	1 (5.6)	0	0
Vomiting	2 (11.1)	1 (5.6)	0
Edema limbs	2 (11.1)	0	0
Fever	1 (5.6)	0	0
Flu-like symptoms	8	3	0
Malaise	0	1 (5.6)	0
Pain	1 (5.6)	0	0
Urinary tract infection	0	1 (5.6)	0
Injection-site reaction	22 (100)	7 (38.8)	0
Creatinine increased	1 (5.6)	0	0
Lymphocyte count decreased	0	1 (5.6)	2 (11.1)
Weight loss	1 (5.6)	1 (5.6)	0
Anorexia	1 (5.6)	2 (11.1)	0
Hyperglycemia	2 (11.1)	0	0
Hyponatremia	2 (11.1)	0	0
Hypophosphatemia	0	1 (5.6)	0
Arthralgia	0	1 (5.6)	0
Back pain	3 (16.7)	0	0
Myalgia	1 (5.6)	1 (5.6)	0
Non-cardiac chest pain	1 (5.6)	0	0
Dizziness	3 (16.7)	0	0

All adverse events are shown. N=number of events. There were no grade 4 treatment-related adverse events. Adverse event grade is according to the National Cancer Institute Common Terminology Criteria for Adverse Events V.5.0.

were excluded if they had previous treatment with Ad-based immunotherapy, chronic hepatitis B or C infection, HIV, untreated central nervous system metastatic disease, or local

treatment of brain metastases within the previous 6 months. Use of herbal products that may decrease PSA levels (such as saw palmetto) was not allowed. Palliative external beam radiation therapy (EBRT) was allowed at the investigator's discretion. The study was approved by the National Cancer Institute's Institutional Review Board and was registered on ClinicalTrials.gov.

Assessment of toxicities

Toxicity was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events V.5.0. Toxicities were identified by review of laboratory studies, medical history, and physical examination. The evaluation period for dose-limiting toxicity (DLT) was 28 days from the start of vaccine administration. A DLT was defined as (a) any grade ≥ 3 toxicity with the exception of transient (≤ 24 hours) grade 3 flu-like symptoms or fever which could be controlled with medical management; (b) transient (≤ 24 hours) grade 3 fatigue, local skin reactions, or rash lasting > 7 days and associated with desquamation, nausea, headache, or emesis that resolved to grade ≤ 1 ; (c) laboratory abnormalities not associated with organ pathology; (d) any grade ≥ 2 autoimmune reaction (except endocrine-related immune toxicity); or (e) immediate hypersensitivity reaction possibly, probably, or definitely related to vaccine treatment. Any grade 3 autoimmune endocrine-related toxicity that had not resolved clinically within 7 days of initiating therapy was also defined as a DLT.

Study design

This was a single-institution, open-label, phase I clinical study with the goal of determining the safety of concurrent administration of three therapeutic vaccines (ETBX-071=PSA, ETBX-061=MUC-1, and ETBX-051=brachyury). The vaccine was developed as part of a Cooperative Research and Development Agreement between the National Cancer Institute and NantBioScience/ImmunityBio. All three vaccines used the same modified Ad5 vector platform and were administered at a single dose level of 5×10^{11} viral particles (VP) per vector. In a prior phase I trial of a similar vaccine, Ad5 [E1-, E2b-]-CEA(6D) (ETBX-011) at the dose level of 5×10^{11} VP per vector was found to be well tolerated, with no DLTs or related severe adverse events (SAEs), and to be the optimal dose for induction of immune responses (NCT01147965).¹³

All three vaccines were given every 3 weeks for three doses (dose de-escalation cohort in first 6 patients only) and then every 8 weeks for up to 1 year (12 patients in the dose-expansion cohort). Clinical responses were evaluated by CT of the chest/abdomen/pelvis and technetium bone scan at baseline, at week 14, and every 8 weeks thereafter. Response to treatment was measured by RECIST V.1.1. In addition to a baseline CT and bone scan, confirmatory scans were obtained up to 6 (not less than 4) weeks following initial documentation of objective response. Treatment lasted 6 weeks in the dose de-escalation cohort (first six patients) and continued until disease progression, unacceptable adverse events (AEs), withdrawal from study, or week 54 in the dose-expansion cohort. The safety and efficacy of the study drugs




Figure 1 PSA changes. This spider plot of PSA measurement data shows percentage change over time: (A) all patients and (B) PSA responders only. PSA, prostate-specific antigen.

were assessed until the end of treatment or for a maximum of 54 weeks.

Immune assays

Blood samples for immune assessments were collected at baseline, week 6, week 14, week 30, and at the end of treatment; in select cases, research blood was also collected at 3 weeks. For peripheral blood mononuclear cell (PBMC) analyses, blood was collected in sodium heparin tubes and PBMCs were separated by Ficoll-Hypaque density gradient separation. The resulting cells were cryopreserved in 90% heat-inactivated human AB serum and 10% dimethyl sulfoxide (DMSO) at a concentration of 1×10^7 cells/mL. For serum assays, blood was collected in serum separator tubes, spun down, and stored at -80°C before analysis.

Serum assays

The presence of anti-PSA antibodies in the serum of patients before and after vaccination was determined by ELISA using methods previously described with slight modifications.^{14, 15} Polyvinyl chloride 96-well microtiter plates were coated in $2 \mu\text{g/mL}$ of a purified, recombinant PSA protein (Fitzgerald Industries, Concord, Massachusetts, USA) or bovine serum albumin (BSA) as a negative control. Serum was diluted at 1:50, 1:250, 1:1250, and 1:6250. Purified mouse anti-PSA immunoglobulin

G1 (IgG₁) antibody (Fitzgerald Industries) was used as a positive control, and an isotype-matched IgG₁ antibody (MOPC-21; Sigma-Aldrich, St. Louis, Missouri, USA) served as a negative control. Titer was defined as the maximum dilution where the absorbance at 450 nm was twice that obtained from the same sample on the control BSA plate. Anti-Ad5 neutralizing antibodies were measured as previously described^{10, 16–18} in serum obtained from patients before and after vaccination.

Serum levels of cytokine/soluble factors were determined before and after vaccination using commercially available kits per the manufacturer's instruction. Levels of serum analytes were also determined in healthy donors obtained from the National Institutes of Health Clinical Center Blood Bank (NCT00001846). Interleukin (IL)-8 was measured by AlphaLISA (PerkinElmer, Waltham, Massachusetts, USA), sCD27 and sCD40L were measured using Instant ELISA kits (Life Technologies, Carlsbad, California, USA), and sPD-1 and sPD-L1 were measured with ELISA kits (Abcam, Cambridge, UK).

PBMC assay to measure antigen-specific T cells

TAA-specific T cells were analyzed using the methods previously described¹⁹ in cryopreserved PBMCs isolated from patients before and after vaccination. PBMCs were

Table 3 PSA responders

Patient ID	Age	Gleason score	Prior therapies	PSA baseline	Lowest PSA	Palliative radiation therapy	PFS weeks
4	77	9	Docetaxel (mCSPC)	8.0	0.9	No	N/A
8	65	9	Docetaxel (mCSPC) Enzalutamide; pulse testosterone (mCRPC)	74.8	37.5	No	22
11	62	8	Abiraterone, enzalutamide, nivolumab, rucaparib, docetaxel, and cabazitaxel	605.0	310.3	Yes×2	38
15	85	9	Docetaxel (mCSPC)	47.4	0.2	Yes	54+
17	65	7	Abiraterone, enzalutamide, and radium 223 (all for mCRPC)	319.3	88.6	Yes	44

mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; N/A, not available; PFS, progression-free survival; PSA, prostate-specific antigen; RT, radiation therapy.

stimulated in vitro with overlapping 15-mer peptide pools encoding PSA, MUC-1, and brachyury and analyzed by intracellular cytokine staining. Peptide pools encoding the human leukocyte antigen (HLA) and CEFT (a mixture of peptides of cytomegalovirus, Epstein-Barr virus, influenza, and tetanus toxin) served as negative and positive controls, respectively. The absolute number of viable CD4+ or CD8+ T lymphocytes producing cytokine (interferon- γ (IFN- γ), tumor necrosis factor- α (TNF α), IL-2) or positive for a degranulation marker (CD107a) at the end of expansion was calculated per 1×10^6 cells plated at the start of the stimulation assay. This calculation takes into account not only the percentage but also the total number of viable antigen-specific T cells expanded in the stimulation assay. The background signal (obtained with the HLA peptide pool) and any value obtained prior to vaccination were subtracted from those obtained after vaccination $([\text{post-TAA-post-HLA}] - [\text{pre-TAA-pre-HLA}])$. A patient was scored as developing a TAA-specific T-cell response during therapy if the patient had more than 250 CD4+ or CD8+ T cells that produced IFN- γ , TNF α , or IL-2 or were positive for CD107a at the end of the stimulation assay per 1×10^6 cells that were plated at the start

of the assay. Patients were scored as having pre-existing TAA-specific T cells if pre-TAA-pre-HLA $>250/1 \times 10^6$ cells and pre-TAA/pre-HLA >2 . Multifunctional TAA responses, defined as CD4+ or CD8+ T cells expressing two or more of IFN- γ , TNF α , IL-2, or CD107a, were also quantified before and after vaccination; the frequency of patients developing a >3 -fold, >10 -fold, or >100 -fold increase in multifunctional TAAs post-vaccination versus pre-vaccination was determined.

Statistical analysis

Summary statistics were used to describe demographic data and baseline performance status characteristics. Descriptive statistics were examined for indications of dose-related toxicity. Disease control rate (DCR) was defined as the percentage of subjects who experience partial response (PR), complete response (CR), or stable disease (SD) lasting for at least 6 months. Progression-free survival (PFS) was defined as the time from the date of first treatment to the date of disease progression or death (any cause) whichever occurs first. OS was evaluated using Kaplan-Meier methods and was defined as the time from the date of first treatment to the date of death from any cause. Immunological parameters were mainly analyzed descriptively and displayed in graphic format using GraphPad Prism V.8 (GraphPad Software, La Jolla, California, USA). In some cases, statistical analysis was performed in RStudio (Boston, Massachusetts, USA); p values for unpaired data were calculated using the Mann-Whitney test, and p values for paired data were calculated using the Wilcoxon matched-pairs signed-rank test.

RESULTS

Patient population

Eighteen patients enrolled between July 2018 and September 2019 received at least one vaccination at the National Cancer Institute in Bethesda, Maryland. Six patients were enrolled in a dose de-escalation cohort, and 12 patients were enrolled in a dose-expansion cohort.




Figure 2 Waterfall plot of best PSA response. PSA response was confirmed in five patients. PSA, prostate-specific antigen.

Patients were predominantly white (83.3%) with a median age of 71.6 years (range, 54–88 years). Eight patients had received ≥ 3 prior lines of therapy for mCRPC. The median number of prior therapies was 3 (range, 0–7). Ten patients received prior immunotherapy regimens, seven of whom received therapeutic cancer vaccines and six of whom were treated with checkpoint inhibitors. Baseline characteristics are summarized in [table 1](#).

Safety

Safety and efficacy were assessed until the end of treatment or for a maximum of 54 weeks. A total of 62 vaccinations were given. Treatment was well tolerated and no DLTs were observed. No SAEs related to treatment were observed. The most common AEs were grade 1 and 2 injection-site reactions (94.4%), flu-like symptoms (58.8%), fatigue (38.9%), and back pain (22.3%). All injection-site reactions resolved without intervention. All AEs are listed in [table 2](#) (the cut-off date was September 1, 2020). Grade 3 SAEs included anemia, dehydration and hypotension (one patient in the dose de-escalation cohort), and lung infection (one patient in the dose-expansion cohort). One patient in the dose de-escalation cohort decided to discontinue therapy due to expected side effects (fever/chills) after the first dose of vaccine. The recommended phase II dose was determined to be 5×10^{11} VP.

Response to therapy

Evaluation of clinical benefits was a secondary objective of this study. Best response (per RECIST V.1.1) was a PR lasting 16 weeks observed in one patient (8.33%) in the dose-expansion cohort. No CRs were observed, but five patients had SD lasting >6 months ([figure 1](#)). The DCR (the percentage of patients who experience a PR, CR, or SD lasting at least 6 months) was 60%. Median PFS was 22 weeks (95% CI: 19.1 to 34). Median PSA was 25.58 ng/mL (range, 0.62–1006 ng/mL). As of September 1, 2020, four patients in the dose de-escalation cohort had died due to progressive disease (PD). Five of six patients in the dose de-escalation cohort completed all three planned doses of vaccine. Median OS was not reached, and 12-month OS probability for all patients was 83.3% (95% CI: 56.8% to 94.3%).

None of the patients in the dose-expansion cohort completed the planned 54 weeks of treatment: five came off study due to PD, two came off study due to preference for another line of therapy, and five came off study per primary investigator discretion due to clinical material availability.

PSA responders

Five patients had confirmed serum PSA declines ([table 3](#), [figures 1B and 2](#)). Two patients received palliative EBRT once to a single painful skeletal area while undergoing vaccine treatment (patient #15 to left humerus; patient #17 to left sacrum); patient #11 received EBRT twice to his lumbar spine. All three patients had prolonged PSA declines lasting

>6 months. In addition, patient #11 had a confirmed PR by RECIST V.1.1, whereas patient #15 has had a sustained PSA response lasting >54 weeks ([figure 1B](#)).

Immune assays

Anti-PSA antibodies were measured in serum collected from patients before and after vaccination. All patients were negative for anti-PSA antibodies at all time points analyzed, including patients with PSA responses following treatment. Neutralizing antibodies to Ad5 were also measured in all patients before and after vaccination. At baseline, 3 of 18 patients had detectable neutralizing Ad5 antibodies. High titers of anti-Ad5 antibodies were induced after multiple vaccinations in all patients, including those who developed PSA responses (online supplemental table 1). Serum cytokine levels of IL-8 and the soluble factors sCD27, sCD40L, SPD-1, and sPD-L1 were also measured in patients before and after vaccination. Prior to therapy, IL-8 and sPD-1 were statistically higher in patients with prostate cancer enrolled in this study than in healthy donors (online supplemental figure 1A and B). Early increases in specific soluble factors, which may be indicative of increased general immune activation, were detected after vaccination. sCD27 and sPD-1 were statistically significantly elevated after 6 weeks of therapy with the Ad5 PSA/MUC-1/brachyury vaccine compared with pretherapy levels (online supplemental figure 1C, D). sCD27 is preferentially derived from activated CD4+ T cells, and studies have shown that immunotherapy can increase this factor.²⁰ There were some trends noted in the change of specific serum analytes between those patients who did versus those who did not develop PSA responses. Levels of sCD40L were decreased in 4 (80%) of 5 patients with PSA responses compared with 1 (8%) of 13 patients who did not develop a PSA response (online supplemental table 2). sCD40L, a functional trimer that is shed from activated T lymphocytes and platelets, has been reported to have an immunosuppressive effect.^{21,22} Conversely, IL-8, a proinflammatory cytokine/chemokine involved in the recruitment of leukocytes to sites of injury and inflammation, increased at an early time point following vaccination in 5 (100%) of 5 patients who developed PSA responses compared with 5 (38%) of 13 who did not develop PSA responses (online supplemental table 2).

Based on PBMC availability and quality, antigen-specific T cells could be evaluated before and after vaccination in 17 of 18 patients. Using the criteria described in the Methods section, pre-existing T cells targeting PSA, MUC-1, or brachyury were detected in 47%, 58%, and 69% of patients, respectively. Vaccination with the Ad5 PSA/MUC-1/brachyury vaccine increased CD4+ and/or CD8+ T-cell responses to at least one TAA encoded by the vaccine in all patients; PSA-specific T cells were developed in 11 (65%) of 17 patients, MUC-1-specific T cells in 17 (100%) of 17 patients, and brachyury-specific T cells in 14 (88%) of 16 patients ([table 4](#)). Sixteen (94%) of 17 patients developed T-cell responses to >1 antigen encoded by the vaccine; 8 patients developed T-cell responses to all three TAAs in the vaccine. Polyfunctional TAA-specific responses, defined as CD4+ or CD8+ T cells that express ≥ 2 of the markers IFN- γ ,

Table 4 Development of TAA-specific T cells during therapy

Any TAA responses	Any TAA responses post-vaccination (vs pre-vaccination)		
PSA	11/17 (65%)		
MUC-1	17/17 (100%)		
Brachyury	14/16 (88%)		
1 antigen	1/17 (6%)		
2 antigens	8/17 (47%)		
3 antigens	8/17 (47%)		
≥2 antigens	16/17 (94%)		
Any antigen	17/17 (100%)		
Multifunctional TAA responses	>3x post vs pre (or if no pre, >100/1×10 ⁶ cells at post)	>10x post vs pre (or if no pre, >1000/1×10 ⁶ cells at post)	>100x post vs pre (or if no pre, >5000/1×10 ⁶ cells at post)
PSA	9/17 (53%)	6/17 (35%)	3/17 (18%)
MUC-1	13/17 (76%)	8/17 (47%)	4/17 (23%)
Brachyury	13/16 (81%)	4/16 (25%)	1/16 (6%)
Any antigen	16/17 (94%)	13/17 (76%)	8/17 (47%)

Frequency of patients developing any CD4+ or CD8+ T-cell responses post-vaccination (vs pre-vaccination). The absolute number of T cells producing IFN- γ , TNF α , or IL-2 or positive for the degranulation marker CD107a per 1×10⁶ peripheral blood mononuclear cells plated at the start of the stimulation assay was calculated. Following subtraction of background and any signal obtained prior to vaccination, a patient was scored as developing any TAA-specific T-cell response during therapy if the patient had >250 CD4+ or CD8+ T cells that produced IFN- γ , TNF α , or IL-2 or were positive for CD107a at the end of the stimulation assay per 1×10⁶ cells that were plated at the start of the assay.

Frequency of patients developing polyfunctional TAA responses (CD4+ and CD8+ T cells expressing two or more of the following: IFN- γ , TNF α , IL-2, or CD107a) post-vaccination versus pre-vaccination. The frequency of patients developing a >3-fold, >10-fold, and >100-fold increase in multifunctional TAA-specific T cells after (vs before) vaccination is indicated.

IFN- γ , interferon- γ ; IL-2, interleukin-2; PSA, prostate-specific antigen; TAA, tumor-associated antigen; TNF α , tumor necrosis factor- α .

TNF α , IL-2, or CD107a, were also measured before and after vaccination. Using the criteria of a >10-fold increase post-vaccination versus pre-vaccination, or the presence of >1000 polyfunctional cells post-vaccination per 1×10⁶ PBMCs (if negative at pre-vaccination), polyfunctional T cells targeting at least one of the antigens tested increased in 13 (76%) of 17 patients after vaccination (table 4). Multifunctional T cells targeting PSA, MUC-1, or brachyury were developed after vaccination in 35%, 47%, and 25% of patients, respectively. All patients with PSA responses developed a >10-fold increase in multifunctional T cells targeting at least one of the three antigens evaluated. The generation of long-lasting polyfunctional T cells, which can persist for years after initial vaccination, has been associated with improved OS.²³

DISCUSSION

We report here the first-in-human trial of the Ad5 PSA/MUC-1/brachyury vaccine platform in patients with mCRPC. The primary objective of this trial was to evaluate the safety and to determine the recommended phase II dose of the Ad5 PSA/MUC-1/brachyury vaccine. As expected, this vaccine was well tolerated and no DLTs were observed, nor were any SAEs attributed to the vaccine. The only grade 3 toxicity attributed to the vaccine was decreased lymphocyte count in two patients. The only grade 2 toxicities attributed to the vaccine were injection-site reactions (n=7) and decreased lymphocyte count (n=1). SAEs unrelated to the vaccine included anemia (n=1), lung infection (n=1), dehydration (n=1) and hypotension (n=1). One patient in

the dose de-escalation cohort discontinued therapy due to expected mild side effects (grade 1 fever and grade 1 chills) after the first dose of vaccine. No biopsies were required in this phase I study. These safety data are consistent with findings from prior clinical trials showing that Ad5 vaccines are safe and well tolerated.^{12 13 16}

There are several limitations to this study, including a small sample size, which requires cautious interpretation of the findings. Although this trial was not powered to evaluate PFS, OS, or clinical benefit, interesting findings were observed. Although no CRs were observed, one patient had a PR lasting 16 weeks and five patients had PFS for at least 6 months. Median PFS was 22 weeks (95% CI: 19.1 to 34). Median OS was not reached, and the 12-month OS probability for all patients was 83.3% (95% CI: 56.8% to 94.3%), indicating that some patients may have derived clinical benefit. The most interesting finding from this study is that of the five patients with a PSA response, two were heavily pretreated (patients #11 and #17) and underwent palliative EBRT due to symptomatic metastases, yet they had prolonged and marked PSA declines lasting from 38 weeks up to 54+weeks, indicating possible synergy between EBRT and the Ad5 PSA/MUC-1/brachyury vaccine (table 3).

We were not able to complete all planned vaccinations in the dose-expansion cohort, and five patients including patients #15 and #17 discontinued treatment early due to clinical material availability. Despite having to discontinue treatment early, patients #15 and #17 had PSA responses lasting 11+ months and 9 months, respectively, after their

last dose of vaccine. Recently, it became clear that the effect of EBRT goes beyond direct tumor killing to promoting systemic anticancer immunity.²⁴ Preclinical studies have demonstrated that the combination of EBRT and vaccine can modulate the immunogenicity of the tumor^{24–26} by increasing its susceptibility to antigen-specific cytotoxic T lymphocytes by changing the tumor surface phenotype.²⁷ In addition, low-dose radiation upregulates major histocompatibility complex (MHC) class I, cellular expression of death receptor Fas/CD95, and intercellular adhesion molecule-1/CD54, promoting tumor cell death via proapoptotic mechanisms and killing by antigen-specific immune cells.^{28–31} Therefore, radiotherapy that promotes the release of tumor neoantigens together with strategies to overcome dominant immunosuppressive pathways, such as therapeutic vaccines, may lead to effective immune-mediated tumor killing, a phenomenon known as the abscopal effect. Although it is uncommon, the abscopal effect is still evaluated in clinical trials.³²

The three TAAs (PSA, MUC-1, and brachyury) encoded in this adenoviral vaccine platform are attractive targets in prostate cancer treatment. Both MUC-1 and brachyury are expressed on several types of human adenocarcinomas, with high expression seen in colorectal cancer, breast cancer, non-small cell lung cancer, and mCRPC.^{33–35} Multiple studies have demonstrated that brachyury and/or MUC-1 overexpression are markers of poor prognosis, treatment resistance to chemotherapy and radiation, and tumor aggressiveness, making targeting those antigens a logical strategy.^{36–40} Preclinical studies have also demonstrated a positive correlation between androgen receptor and MUC-1, including MUC-1's contribution to the generation of neuroendocrine prostate cancer, making it a viable target for prostate cancer immunotherapy.⁴¹

Multiple therapeutic cancer vaccine trials have been conducted using a combination of TAAs, but this is the first trial to use this triad of TAAs (PSA, MUC-1, and brachyury). Immune correlative studies have revealed interesting results. The Ad5 PSA/MUC-1/brachyury vaccine generated CD4+ and/or CD8+ T-cell responses to at least one TAA encoded by the vaccine in all patients. Notably, all but one patient developed T cells to more than one antigen encoded by the vaccine, and nearly half of the patients (47%) developed responses after vaccination to all three TAAs encoded by the vaccine. Furthermore, polyfunctional TAA-specific responses, defined as CD4+ or CD8+ T cells that express ≥ 2 of the markers IFN- γ , TNF α , IL-2, or CD107a, were increased in the majority of patients after vaccination, and all patients with PSA declines had a >10-fold increase in multifunctional T cells with therapy. These increases in antigen-specific T cells were observed despite all patients developing anti-Ad5 neutralizing antibodies after multiple vaccinations. This study adds to the existing evidence^{12 15 19 42–45} that anti-tumor vaccines directed against PSA, MUC-1, and brachyury are well tolerated and can generate antitumor immune responses.

CONCLUSIONS

This is the first trial to investigate the effects of Ad5 PSA/MUC-1/brachyury in patients with mCRPC. The primary end points were met and there were no DLTs. The Ad5 PSA/MUC-1/brachyury vaccine platform is well tolerated with acceptable safety and produced PSA decreases and SD lasting >6 months in some patients, especially in those who received concurrent palliative EBRT. Its potential for combination with different immuno-oncology agents makes it a promising agent for future studies. Subsequent trials will evaluate the use of this vaccine in combination with checkpoint inhibitors and/or other immune modulators, including palliative EBRT.

Twitter Marijo Bilusic @mbilusic, Charalampos Floudas @chfloudas, Houssein Abdul Sater @HsaterMD and James L Gulley @gulleyj1

Acknowledgements The authors would like to thank the patients and research staff who made this trial possible. Also, the authors would like to thank Bonnie L. Casey and Debra Weingarten for editorial assistance in the preparation of this manuscript, and Angie Schwab and Keanan Wright for technical assistance with immune assays. JS and CP have patents involving agonist epitopes for brachyury, MUC-1, and PSA.

Contributors MB, JS, and JG designed the study. MB, SM, FK, RM, CJ, JST, JR, HAS, and JG treated patients and acquired clinical data. MB and JM analyzed the clinical data. SR and PSS developed the vaccine. RD, YT, CP, and JS analyzed and interpreted immune assay data. MB wrote the manuscript. MB, SM, RM, FK, JST, JS, JR, HAS, and JG contributed to overall data interpretation and editing of the manuscript. All authors critically reviewed the manuscript. All authors read and approved the final manuscript.

Funding This research was supported by the Intramural Research Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, and via a Cooperative Research and Development Agreement (CRADA) between the National Cancer Institute and NantBioScience/ImmunityBio.

Competing interests ImmunityBio authors are employees of ImmunityBio, Inc.

Patient consent for publication Not required.

Ethics approval All patients gave written informed consent for participation. This study was approved by the National Cancer Institute's Institutional Review Board. The trial registration number is NCT03481816.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Marijo Bilusic <http://orcid.org/0000-0003-1020-689X>
 Ravi A Madan <http://orcid.org/0000-0001-5106-8636>
 Fatima Karzai <http://orcid.org/0000-0002-3244-1332>
 Caroline Jochems <http://orcid.org/0000-0002-9000-9855>
 Charalampos Floudas <http://orcid.org/0000-0002-0020-237X>
 Houssein Abdul Sater <http://orcid.org/0000-0003-1975-3726>
 Jeffrey Schlom <http://orcid.org/0000-0001-7932-4072>
 James L Gulley <http://orcid.org/0000-0002-6569-2912>

REFERENCES

- Cunha AC, Weigle B, Kiessling A, *et al*. Tissue-specificity of prostate specific antigens: comparative analysis of transcript levels in prostate and non-prostatic tissues. *Cancer Lett* 2006;236:229–38.
- Cole G, McCaffrey J, Ali AA, *et al*. Dna vaccination for prostate cancer: key concepts and considerations. *Cancer Nanotechnol* 2015;6:2.

- 3 Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics--theory. *Urology* 1981;17:40–53.
- 4 Gulley JL, Borre M, Vogelzang NJ, et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. *J Clin Oncol* 2019;37:1051–61.
- 5 Imler JL. Adenovirus vectors as recombinant viral vaccines. *Vaccine* 1995;13:1143–51.
- 6 Tatsis N, Ertl HCJ. Adenoviruses as vaccine vectors. *Mol Ther* 2004;10:616–29.
- 7 Gabitzsch ES, Jones FR. New recombinant Ad5 vector overcomes Ad5 immunity allowing for multiple safe, homologous immunizations. *J Clin Cellular Immunol* 2012;2012:1–4.
- 8 Osada T, Yang XY, Hartman ZC, et al. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. *Cancer Gene Ther* 2009;16:673–82.
- 9 Gabitzsch ES, Xu Y, Yoshida LH, et al. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses. *Immunol Lett* 2009;122:44–51.
- 10 Gabitzsch ES, Xu Y, Balint JP, et al. Induction and comparison of SIV immunity in Ad5 naive and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine. *Vaccine* 2011;29:8101–7.
- 11 Gabitzsch ES, Tsang KY, Palena C, et al. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. *Oncotarget* 2015;6:31344–59.
- 12 Gatti-Mays ME, Redman JM, Donahue RN, et al. A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer. *Oncologist* 2020;25:479–899.
- 13 Balint JP, Gabitzsch ES, Rice A, et al. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. *Cancer Immunol Immunother* 2015;64:977–87.
- 14 Madan RA, Mohebtash M, Arlen PM, et al. Iplimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. *Lancet Oncol* 2012;13:501–8.
- 15 Heery CR, Palena C, McMahon S, et al. Phase I study of a Poxviral TRICOM-Based vaccine directed against the transcription factor Brachyury. *Clin Cancer Res* 2017;23:6833–45.
- 16 Morse MA, Chaudhry A, Gabitzsch ES, et al. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. *Cancer Immunol Immunother* 2013;62:1293–301.
- 17 Gabitzsch ES, Xu Y, Balint JP, et al. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. *Cancer Immunol Immunother* 2010;59:1131–5.
- 18 Gabitzsch ES, Xu Y, Balcaitis S, et al. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. *Cancer Gene Ther* 2011;18:326–35.
- 19 Gatti-Mays ME, Strauss J, Donahue RN, et al. A phase I dose-escalation trial of BN-CV301, a recombinant Poxviral vaccine targeting MUC1 and CEA with costimulatory molecules. *Clin Cancer Res* 2019;25:4933–44.
- 20 Huang J, Jochems C, Anderson AM, et al. Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity. *J Immunol* 2013;190:6250–8.
- 21 Schlom J, Jochems C, Gulley JL, et al. The role of soluble CD40L in immunosuppression. *Oncoimmunology* 2013;2:e22546.
- 22 Huang J, Jochems C, Talaie T, et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. *Blood* 2012;120:3030–8.
- 23 Wimmers F, Aarntzen EHJG, Duiveman-deBoer T, et al. Long-lasting multifunctional CD8⁺ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. *Oncoimmunology* 2016;5:e1067745.
- 24 Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. *J Natl Cancer Inst* 2013;105:256–65.
- 25 Garnett-Benson C, Hodge JW, Gameiro SR. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. *Semin Radiat Oncol* 2015;25:46–53.
- 26 Formenti SC. Silvia Formenti on the promise of combining radiotherapy and immunotherapy to treat cancer. *Oncology* 2016;30:289–92.
- 27 Gameiro SR, Jammeh ML, Wattenberg MM, et al. Radiation-Induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. *Oncotarget* 2014;5:403–16.
- 28 Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. *J Immunol* 2003;170:6338–47.
- 29 Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. *Science* 1995;270:1189–92.
- 30 Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. *Mol Biotechnol* 2003;25:19–30.
- 31 Gameiro SR, Ardiani A, Kwilas A, et al. Radiation-Induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. *Oncoimmunology* 2014;3:e28643.
- 32 Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. *Clin Cancer Res* 2009;15:5379–88.
- 33 Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. *Nat Rev Cancer* 2004;4:45–60.
- 34 Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. *Cancer Biol Ther* 2009;8:1197–203.
- 35 Yin L, Kufe D. Muc1-C oncoprotein blocks terminal differentiation of chronic myelogenous leukemia cells by a ROS-mediated mechanism. *Genes Cancer* 2011;2:56–64.
- 36 Roselli M, Fernando RI, Guadagni F, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. *Clin Cancer Res* 2012;18:3868–79.
- 37 Kilic N, Feldhaus S, Kilic E, et al. Brachyury expression predicts poor prognosis at early stages of colorectal cancer. *Eur J Cancer* 2011;47:1080–5.
- 38 Pinto F, Pértega-Gomes N, Pereira MS, et al. T-Box transcription factor Brachyury is associated with prostate cancer progression and aggressiveness. *Clin Cancer Res* 2014;20:4949–61.
- 39 Palena C, Roselli M, Litzinger MT, et al. Overexpression of the EMT driver Brachyury in breast carcinomas: association with poor prognosis. *J Natl Cancer Inst* 2014;106. doi:10.1093/jnci/dju054. [Epub ahead of print: 09 May 2014].
- 40 Haro A, Yano T, Kohno M, et al. Expression of Brachyury gene is a significant prognostic factor for primary lung carcinoma. *Ann Surg Oncol* 2013;20 Suppl 3:509–16.
- 41 Wong N, Major P, Kapoor A, et al. Amplification of MUC1 in prostate cancer metastasis and CRPC development. *Oncotarget* 2016;7:83115–33.
- 42 Collins JM, Donahue RN, Tsai Y-T, et al. Phase I trial of a modified vaccinia Ankara priming vaccine followed by a fowlpox virus boosting vaccine modified to express Brachyury and costimulatory molecules in advanced solid tumors. *Oncologist* 2020;25:560–1006.
- 43 Heery CR, Singh BH, Rauckhorst M, et al. Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor Brachyury. *Cancer Immunol Res* 2015;3:1248–56.
- 44 Duggan MC, Jochems C, Donahue RN, et al. A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN- α -2b in patients with CEA-expressing carcinomas. *Cancer Immunol Immunother* 2016;65:1353–64.
- 45 Abdul Sater H, Martí JL, Donahue RN, et al. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. *J Immunother Cancer* 2020;8:e000655.